translation agency

Quantitation of HIV-1 in patients' plasma using Q-NASBA.
Jiang MK; Taschner JJ; Highbarger HC; Metcalf JA; Lane HC; Dewar RL;
November 30, 1996
3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:155. Unique

The Organon Teknika Q-NASBA was used to quantitate HIV-1 levels in the plasma of patients enrolled in clinical trials of antiretroviral and immune-based therapies at the National Institute of Allergy and Infectious Diseases HIV Clinic. Results were compared to those obtained using branched DNA (bDNA) signal amplification and ICD p24 serum antigen. These results were compared with the total CD4 cell counts from each patient. A.) Twenty-one plasma samples from 7 patients (CD4 cell counts less than 300 cells/mm3), treated with MK-639 (Merck protease inhibitor) were tested for changes in viral load using the three methods. HIV-1 RNA was detectable in all patients before the initiation of therapy. Both the Q-NASBA and bDNA assays showed decreases in viral burden in all patients after initiation of therapy. p24 serum antigen levels also declined in those patients who were antigenemic prior to therapy (n=6). There was a concomitant increase in the patients' CD4 cell counts. B.) Thirty-five plasma samples from 6 patients (CD4 cell counts greater than 200 cells/mm3) which had previously tested below the bDNA assay cutoff of 10,000 RNA copies/mL and were p24 antigen-positive, were retested using Q-NASBA. Twenty-two of the 35 samples contained detectable amounts of virus by Q-NASBA (cutoff = 1000 RNA copies/mL). Additional data are being accumulated from samples tested for virus using a more sensitive bDNA assay. Both Q-NASBA and bDNA can be used to monitor changes in HIV-1 levels in plasma in response to therapy. Q-NASBA maybe more useful when sample volumes and/or virus levels are low.

CD4 Lymphocyte Count DNA, Viral/*BLOOD HIV Core Protein p24/BLOOD HIV Infections/DRUG THERAPY/*VIROLOGY HIV Protease Inhibitors/THERAPEUTIC USE HIV-1/*ISOLATION & PURIF Human ABSTRACT